Literature DB >> 15780588

Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes.

George S Baillie1, Miles D Houslay.   

Abstract

Various methods reveal that cyclic AMP (cAMP) signalling in cells is compartmentalised. These methods use FRET probes based upon either protein kinase A (PKA) or EPAC, cAMP-gated ion channels, or the selective activation of AKAP-anchored PKA isoforms. The basis of compartmentalisation involves point sources of cAMP generation within sub-domains of the plasma membrane coupled to degradation by spatially segregated, anchored forms of cAMP phosphodiesterases. cAMP-specific phosphodiesterase-4 (PDE4) isoforms play a central role in determining compartmentalisation, as exemplified in cardiac myocytes and T cells. The PKA phosphorylation status of the beta2-adrenoreceptor, and hence its ability to switch its signalling from G(s) to G(i) and thus to activate ERK, is regulated dynamically by the agonist-stimulated recruitment of PDE4 to the receptor in complex with beta-arrestin. The co-receptor CD28 enhances signalling through the T-cell receptor by recruiting a PDE4/beta-arrestin complex, which then attenuates PKA phosphorylation of Csk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780588     DOI: 10.1016/j.ceb.2005.01.003

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  41 in total

1.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

2.  Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.

Authors:  Xiang Li; George S Baillie; Miles D Houslay
Journal:  J Biol Chem       Date:  2009-04-16       Impact factor: 5.157

3.  Arresting times for PTEN.

Authors:  Miles D Houslay
Journal:  EMBO J       Date:  2011-07-06       Impact factor: 11.598

Review 4.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

5.  Reciprocal regulation of PKA and Rac signaling.

Authors:  Verena A Bachmann; Anna Riml; Roland G Huber; George S Baillie; Klaus R Liedl; Taras Valovka; Eduard Stefan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-08       Impact factor: 11.205

6.  Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.

Authors:  Graeme B Bolger; George S Baillie; Xiang Li; Martin J Lynch; Pawel Herzyk; Ahmed Mohamed; Lisa High Mitchell; Angela McCahill; Christian Hundsrucker; Enno Klussmann; David R Adams; Miles D Houslay
Journal:  Biochem J       Date:  2006-08-15       Impact factor: 3.857

7.  Regulation of amygdalar PKA by beta-arrestin-2/phosphodiesterase-4 complex is critical for fear conditioning.

Authors:  Yuting Li; Haohong Li; Xing Liu; Guobin Bao; Yezheng Tao; Ziyan Wu; Peng Xia; Chunfu Wu; Baoming Li; Lan Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

8.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

9.  An evolutionary analysis of cAMP-specific Phosphodiesterase 4 alternative splicing.

Authors:  Keven R Johnson; Jessie Nicodemus-Johnson; Robert S Danziger
Journal:  BMC Evol Biol       Date:  2010-08-11       Impact factor: 3.260

Review 10.  Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.

Authors:  Satish Cheepala; Jean-Sebastien Hulot; Jessica A Morgan; Yassine Sassi; Weiqiang Zhang; Anjaparavanda P Naren; John D Schuetz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-10-16       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.